Karyopharm Therapeutics Inc Market Cap ($15.00 Million)
Market Cap & Net Worth: Karyopharm Therapeutics Inc (KPTI)
Karyopharm Therapeutics Inc market cap. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has a market capitalization of $15.00 Million ($15.00 Million) as of November 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25845 globally and #5442 in its home market, demonstrating a 21.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Karyopharm Therapeutics Inc's stock price $0.66 by its total outstanding shares 22662943 (22.66 Million). Also see Karyopharm Therapeutics Inc (KPTI) cash conversion ratio for how efficiently the company converts equity into cash flow.
Karyopharm Therapeutics Inc Market Cap History (2015–2026)
Karyopharm Therapeutics Inc market cap history from 2015 to 2026. Data shows change from $300.28 Million to $15.00 Million (-24.07% CAGR). Check current stock price of Karyopharm Therapeutics Inc for real-time trading data and today's change.
Index Memberships
Karyopharm Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #720 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #2365 of 3165 |
Weight: Karyopharm Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Karyopharm Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Karyopharm Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore KPTI shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.14x
Karyopharm Therapeutics Inc's market cap is 1.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $213.03 Million | $154.00K | -$109.58 Million | 1383.32x | N/A |
| 2017 | $217.56 Million | $1.60 Million | -$128.98 Million | 135.55x | N/A |
| 2018 | $212.35 Million | $30.34 Million | -$178.41 Million | 7.00x | N/A |
| 2019 | $434.45 Million | $40.89 Million | -$199.59 Million | 10.62x | N/A |
| 2020 | $350.82 Million | $108.08 Million | -$196.27 Million | 3.25x | N/A |
| 2021 | $145.72 Million | $209.82 Million | -$124.09 Million | 0.69x | N/A |
| 2022 | $77.05 Million | $157.07 Million | -$165.29 Million | 0.49x | N/A |
| 2023 | $19.60 Million | $146.03 Million | -$143.10 Million | 0.13x | N/A |
| 2024 | $15.33 Million | $145.24 Million | -$76.42 Million | 0.11x | N/A |
| 2025 | $166.80 Million | $146.07 Million | -$196.04 Million | 1.14x | N/A |
Competitor Companies of KPTI by Market Capitalization
Companies near Karyopharm Therapeutics Inc in the global market cap rankings as of November 2, 2026. Also see Karyopharm Therapeutics Inc total assets for a full breakdown of the balance sheet.
Key companies related to Karyopharm Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Karyopharm Therapeutics Inc (2015–2026)
Market capitalization of Karyopharm Therapeutics Inc from 2015 to today. Between 2015 and today, Karyopharm Therapeutics Inc's market cap moved from $300.28 Million to $ 15.00 Million, with a yearly change of -24.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $15.00 Million | -91.01% |
| 2025 | $166.80 Million | +988.27% |
| 2024 | $15.33 Million | -21.82% |
| 2023 | $19.60 Million | -74.56% |
| 2022 | $77.05 Million | -47.12% |
| 2021 | $145.72 Million | -58.46% |
| 2020 | $350.82 Million | -19.25% |
| 2019 | $434.45 Million | +104.59% |
| 2018 | $212.35 Million | -2.40% |
| 2017 | $217.56 Million | +2.13% |
| 2016 | $213.03 Million | -29.06% |
| 2015 | $300.28 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Karyopharm Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.00 Million USD |
| MoneyControl | $15.00 Million USD |
| MarketWatch | $15.00 Million USD |
| marketcap.company | $15.00 Million USD |
| Reuters | $15.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more